Phase 2 Study of AZD2014, a Dual mTORC1/mTORC1 Inhibitor,for NF2 Patients with Progressive or Symptomatic Meningiomas
Technical Report,15 May 2016,14 May 2017
Massachusetts General Hospital Boston United States
Pagination or Media Count:
Meningiomas are common in neurofibromatosis 2 NF2 patients with a cumulative incidence of80 by 70 years of age. Meningiomas that progress despite surgery and radiation are an important unmet medical need for these patients. To date, no chemotherapy has demonstrated efficacy against NF2-related meningiomas. Our laboratory studies have shown that treatment of primary meningioma cells with AZD2014, a mTORC1mTORC2 inhibitor, leads to decreased cell viabilityproliferation. Thus, we hypothesize that AZD2014 will be effective in treating symptomatic or progressive meningiomas in NF2 patients.
- Medicine and Medical Research